Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranylcypromine versus lithium augmentation for treatment-resistant unipolar depression
2012-001209-26Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in treatment-resistant depression (TRD) comparing Tranylcypromine with Lithium augmentation (2 arms). Primary endpoint: Response rate. Started Sep 2013; status: terminated.
02
Drugs
tranylcypromine + trifluoperazinelithium carbonate
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2012-001209-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001209-26.